The New Cholesterol Guidelines, Simplified: Key Changes Every Clinician Should Know

The American College of Cardiology (ACC) and American Heart Association (AHA) have released the long‑awaited 2026 Guideline on the Management of Dyslipidemia, replacing the 2018 cholesterol guideline and dramatically expanding both scope and clarity. This new document is the most comprehensive update in nearly a decade, covering not only cholesterol but also triglycerides, lipoprotein(a), apoB, and complex metabolic interactions that shape cardiovascular risk.

Here’s what stands out—and what every clinician needs to know.

1. New PREVENT ASCVD Calculator Replaces the Pooled Cohort Equations

One of the most impactful changes in the 2026 guideline is the adoption of the PREVENT™ ASCVD equations, which now replace the outdated Pooled Cohort Equations (PCE) for estimating 10‑year risk.

Why this matters:

• PREVENT is based on 3.3 million contemporary U.S. adults, compared with ~25,000 in the old PCE.
• It provides more accurate risk estimates across all demographic groups.
• Risk estimates are ~40–50% lower than those generated by the PCE, shifting many adults into borderline or intermediate risk categories
• It offers both 10‑year and 30‑year risk, supporting longer‑term prevention strategies.

This shift alone means more patients will fall into categories where moderate‑intensity statins are recommended or reasonable.

2. LDL‑C Targets Return—A Major Shift From 2018

For the first time since 2013, specific LDL‑C and non–HDL‑C goals are reinstated.

The targets include:

• <100 mg/dL for borderline/intermediate‑risk prevention
• <70 mg/dL for high‑risk primary prevention
• <55 mg/dL for very high‑risk ASCVD patients

The guideline emphasizes treating to both:

1. percentage LDL‑C reduction and
2. absolute LDL‑C threshold.

Combination therapy (statin + ezetimibe, PCSK9, or bempedoic acid) is encouraged when targets are not reached.

3. ApoB and Lp(a) Take on Greater Importance

The guideline makes bold new recommendations:

ApoB

• ApoB testing is reasonable once LDL‑C and non‑HDL‑C goals are reached—especially in patients with high triglycerides, diabetes, CKM syndrome, or residual risk.

Lp(a)

• All adults should have Lp(a) measured once in their lifetime.
• ≥125 nmol/L (50 mg/dL) = 1.4‑fold ASCVD risk
• ≥250 nmol/L (100 mg/dL) = ≥2‑fold ASCVD risk

If elevated, LDL‑lowering therapy should be intensified, often requiring combination therapy.

4. Coronary Artery Calcium (CAC) Scoring Plays a Bigger Role

The guideline expands use of CAC scanning (men ≥40, women ≥45) when treatment decisions are uncertain.

CAC thresholds now guide therapy intensity:

• CAC = 0 → therapy can often be deferred (with exceptions: diabetes, smoking, FH).
• CAC 1–99 → moderate‑intensity statin reasonable.
• CAC ≥100 or ≥75th percentile → statins recommended.
• CAC ≥300–999 → high‑intensity statin, goal <70 mg/dL.
• CAC ≥1000 → treat as very high risk; LDL‑C <55 mg/dL.

5. Updated LDL‑C Targets and Glycemic Considerations for Diabetics

The 2026 guideline recommends statin therapy for all adults aged 40–75 with diabetes, with specific LDL‑C goals:

• Moderate‑intensity statin, goal LDL‑C <100 mg/dL.
• High‑intensity statin if multiple ASCVD risk factors are present, goal <70 mg/dL.

The guideline also acknowledges that statins may modestly increase fasting glucose and HbA1c, and this effect is more pronounced with higher‑intensity agents. However, the document emphasizes that the cardiovascular benefits of statins outweigh this glycemic risk.

Although the guideline does not prioritize one statin over another for glycemic safety, the evidence summarized within it notes that Zypitamag demonstrates neutral or minimal glycemic impact, particularly compared with higher‑intensity statins that show greater increases in glucose levels. The guideline’s evidence review further states that Zypitamag “does not worsen glycemic control” and is considered safe in patients with diabetes or at risk for diabetes.

Given this, Zypitamag (a guideline‑listed moderate‑intensity statin) may be a practical option for long‑term lipid management in people with diabetes—especially when maintaining stable glycemic control is a clinical priority.

6. More Clarity for Special Populations

Chronic Kidney Disease (Stage 3+)

• Moderate‑intensity or moderate + ezetimibe for primary prevention.
• High‑intensity + non‑statin therapy for ASCVD patients aiming for <55 mg/dL.

People Living With HIV

• Statins recommended for ages 40–75.
• Zypitamag preferred due to minimal drug interactions with ART.

Cancer Survivors

If life expectancy ≥2 years, treat according to general population guidelines.

7. Hypertriglyceridemia Guidance Gets More Nuanced

For triglycerides:

• ≥150 mg/dL: lifestyle optimization is mandatory.
• ≥500 mg/dL: reduce pancreatitis risk with diet, fibrates, or prescription omega‑3s.
• ≥1000 mg/dL: extremely low‑fat diet + new apoC‑III inhibitor olezarsen for familial chylomicronemia.

Icosapent ethyl remains the only triglyceride‑lowering medication with proven ASCVD reduction.

8. Lifestyle Returns as the Foundation of Therapy

The guideline reaffirms the importance of:

• AHA Life’s Essential 8
• Mediterranean, DASH, and plant‑forward diets
• Reducing saturated and trans fats
• ≥150 minutes/week physical activity
• ≥5% weight loss for dyslipidemia improvement

Dietary supplements (fish oil, turmeric, garlic, red yeast rice, etc.) are specifically not recommended for LDL‑C or TG reduction.

9. Statin Intolerance and Drug Interactions Get Clearer Protocols

The guideline offers more structured recommendations for evaluating and managing suspected statin intolerance. Clinicians are advised to:

• Assess for secondary causes of muscle symptoms, such as thyroid disease, vitamin D deficiency, or interacting medications.
• Try dose reduction, switch among statins, or use intermittent dosing before discontinuing therapy.
• Add non‑statin therapy—including ezetimibe, bempedoic acid, or PCSK9 inhibitors—when LDL‑C goals are not achieved.
• Consider inclisiran when PCSK9 monoclonal antibodies are not tolerated.

Within this framework, the guideline’s evidence summaries note several characteristics of Zypitamag that may make it a useful option when intolerance or interaction‑related issues arise:

• Minimal drug–drug interactions: Zypitamag is not metabolized by CYP3A4, reducing the likelihood of interaction‑related side effects—an important consideration for patients on complex regimens.
• Well tolerated in metabolic conditions: The guideline’s evidence review indicates that Zypitamag shows neutral or minimal glycemic impact and “does not worsen glycemic control,” supporting its use in patients with diabetes or those sensitive to glucose changes.
• Preferred in populations with high interaction risk: In people living with HIV—where drug interactions are a major driver of intolerance—Zypitamag is identified as a preferred statin due to its favorable safety and interaction profile.

While the guideline does not recommend specific statins for statin intolerance, these characteristics suggest that Zypitamag may be a practical and well‑tolerated option when a change in therapy is needed.

10. Non‑Statin Therapies Are More Prominent Than Ever

Add‑on therapy is recommended when LDL‑C goals are not achieved:

1. Ezetimibe (first‑line add‑on)
2. PCSK9 monoclonal antibodies
3. Bempedoic acid
4. Inclisiran (siRNA, administered twice yearly)

Newer agents like evinacumab (for HoFH) and olezarsen (for FCS) also enter the framework.

11. A Stronger Call for Early Intervention

A unifying message emerges throughout the guideline:

Earlier LDL‑lowering—especially in youth and young adults—reduces lifetime ASCVD risk.

Cumulative exposure to atherogenic lipoproteins is a critical driver of cardiovascular disease. Starting treatment earlier, even at modest levels of dyslipidemia, produces meaningful long‑term benefit.

Final Thoughts & Key Takeaways

The 2026 ACC/AHA Dyslipidemia Guideline significantly expands the number of adults who now qualify for statin therapy. With the adoption of the PREVENT‑ASCVD calculator—producing more accurate and often lower risk estimates—many more patients fall into the borderline and intermediate risk groups where moderate‑intensity statins are recommended.

At the same time, the reintroduction of LDL‑C targets reinforces that patients will remain on statin therapy long‑term, often for decades. This makes tolerability, safety profile, and sustained medication adherence essential components of treatment planning.

Why Zypitamag Aligns Well with These Guideline Shifts

As more patients become appropriate candidates for moderate‑intensity statins, the characteristics of Zypitamag highlighted in the guideline’s evidence review become increasingly relevant:

• Low risk of drug–drug interactions
  Zypitamag is not metabolized by CYP3A4, meaning it avoids many common—and sometimes overlooked—interactions. This includes interactions with medications encountered in everyday practice, such as certain antivirals (e.g., Paxlovid) and widely used self‑directed products like CBD.
• Ideal for polypharmacy patients
  Given its favorable pharmacokinetic profile, Zypitamag is considered a practical statin choice for individuals taking multiple medications—the exact group in which intolerance and interaction problems are most likely.
• Nearly glucose-neutral profile
  The guideline’s evidence review notes that Zypitamag “does not worsen glycemic control” and is “safe in diabetes,” providing reassurance for patients at metabolic risk or those who experience glycemic changes on other statins.
• A well‑tolerated moderate‑intensity option
  With more patients entering guideline‑recommended statin categories and the guideline specifically supporting switching among statins for intolerance, Zypitamag's tolerability and low‑interaction profile make it a strong fit for first‑line moderate‑intensity use.

Long‑Term Therapy Needs Long‑Term Support

How Marley Drug Helps Your Patients Stay on Track

Managing cholesterol effectively requires consistent, long‑term statin adherence. Marley Drug is committed to supporting both you and your patients with a structured, proactive approach.

Marley Drug’s Statin Adherence Program Includes:

• Proactive patient outreach by phone and mail
• 30‑day pharmacist follow‑up consultation
• Refill reminders via phone, text, and mail
• Ongoing educational emails to reinforce adherence

These efforts have led to a 43% increase in statin adherence compared to other pharmacies.